Chronic lung diseases, encompassing conditions like asthma and COPD, are of global health concern. Central to some of these diseases is eosinophilic inflammation, where eosinophils, white blood cells integral to allergic responses, become dysregulated in the lungs, causing tissue damage. While traditionally linked to asthma, recent studies reveal eosinophilic involvement in other lung diseases, including those associated with hypereosinophilic syndrome and vasculitis. Delving into the molecular mechanisms behind this inflammation is crucial, as it paves the way for targeted therapeutic strategies. As research unveils pathways that sustain eosinophilic activity in lung tissues, novel treatments, including monoclonal antibodies and small molecules, emerge. Also, environmental risk factors such as air pollution and exposure to allergens, and infections including parasitosis and fungi has been linked to asthma with eosinophilic inflammation. Understanding this intricate relationship between eosinophilic inflammation, eosinophilic activation, intercellular interactions, molecular insights, and therapeutic interventions is vital for both academia and clinical application.
Eosinophilic inflammation, historically associated with conditions like asthma, is now recognized to have broader implications in other chronic lung diseases. However, the molecular dynamics governing this inflammation are not fully delineated, presenting a gap in targeted therapeutic approaches. The objective of this Research Topic is to uncover the intricate molecular mechanisms behind eosinophilic inflammation. Recent breakthroughs have identified mediators and signaling molecules that regulate eosinophil activity in the lungs, paving the way for potential treatments, including monoclonal antibodies and small molecule inhibitors. Intrinsic abnormalities of eosinophil activation such as in the hypeosinophilic syndrome may be involved. By synthesizing these discoveries, we aim to understand their clinical relevance and harness them for effective therapeutic strategies, bridging the current knowledge gap in the treatment of chronic lung conditions driven by eosinophilic inflammation.
This Research Topic is dedicated to advancing the understanding of eosinophilic inflammation and its implications in chronic lung diseases (CLD), specifically focusing on conditions such as COPD, asthma, eosinophilic granulomatosis with angiitis and allergic bronchopulmonary fungosis. Our goal is to create a multidisciplinary platform for discussion about the latest insights in the management, diagnosis, and treatment of these diseases in the context of eosinophilic inflammation and activation.
Information for Authors:
For this research topic, we welcome a diverse range of articles to foster comprehensive discussions. We invite:
Original Research: Articles presenting novel findings on eosinophilic inflammation in CLD, its epidemiological and molecular underpinnings, and potential therapeutic strategies.
Brief Research Reports: Concise reports highlighting preliminary data or significant findings in the domain.
Case Reports: Detailed accounts of unique clinical cases that shed light on eosinophilic inflammation's role in CLD or provide novel management or mechanistic insights.
Reviews: Comprehensive analyses of existing literature, with a focus on recent advancements, controversies, or gaps in the field, including systematic reviews and meta-analysis
Submissions should address one or more of the following topics:
Clinical diagnosis and rehabilitation strategies for eosinophilic inflammation-driven CLD.
Detailed exploration of the pathophysiology of CLD, with emphasis on eosinophilic inflammation.
Deep dives into the mechanisms underlying eosinophilic inflammation and activation in CLD and their potential clinical applications.
Identifying and analyzing risks associated with eosinophilic inflammation in CLD.
Chronic lung diseases, encompassing conditions like asthma and COPD, are of global health concern. Central to some of these diseases is eosinophilic inflammation, where eosinophils, white blood cells integral to allergic responses, become dysregulated in the lungs, causing tissue damage. While traditionally linked to asthma, recent studies reveal eosinophilic involvement in other lung diseases, including those associated with hypereosinophilic syndrome and vasculitis. Delving into the molecular mechanisms behind this inflammation is crucial, as it paves the way for targeted therapeutic strategies. As research unveils pathways that sustain eosinophilic activity in lung tissues, novel treatments, including monoclonal antibodies and small molecules, emerge. Also, environmental risk factors such as air pollution and exposure to allergens, and infections including parasitosis and fungi has been linked to asthma with eosinophilic inflammation. Understanding this intricate relationship between eosinophilic inflammation, eosinophilic activation, intercellular interactions, molecular insights, and therapeutic interventions is vital for both academia and clinical application.
Eosinophilic inflammation, historically associated with conditions like asthma, is now recognized to have broader implications in other chronic lung diseases. However, the molecular dynamics governing this inflammation are not fully delineated, presenting a gap in targeted therapeutic approaches. The objective of this Research Topic is to uncover the intricate molecular mechanisms behind eosinophilic inflammation. Recent breakthroughs have identified mediators and signaling molecules that regulate eosinophil activity in the lungs, paving the way for potential treatments, including monoclonal antibodies and small molecule inhibitors. Intrinsic abnormalities of eosinophil activation such as in the hypeosinophilic syndrome may be involved. By synthesizing these discoveries, we aim to understand their clinical relevance and harness them for effective therapeutic strategies, bridging the current knowledge gap in the treatment of chronic lung conditions driven by eosinophilic inflammation.
This Research Topic is dedicated to advancing the understanding of eosinophilic inflammation and its implications in chronic lung diseases (CLD), specifically focusing on conditions such as COPD, asthma, eosinophilic granulomatosis with angiitis and allergic bronchopulmonary fungosis. Our goal is to create a multidisciplinary platform for discussion about the latest insights in the management, diagnosis, and treatment of these diseases in the context of eosinophilic inflammation and activation.
Information for Authors:
For this research topic, we welcome a diverse range of articles to foster comprehensive discussions. We invite:
Original Research: Articles presenting novel findings on eosinophilic inflammation in CLD, its epidemiological and molecular underpinnings, and potential therapeutic strategies.
Brief Research Reports: Concise reports highlighting preliminary data or significant findings in the domain.
Case Reports: Detailed accounts of unique clinical cases that shed light on eosinophilic inflammation's role in CLD or provide novel management or mechanistic insights.
Reviews: Comprehensive analyses of existing literature, with a focus on recent advancements, controversies, or gaps in the field, including systematic reviews and meta-analysis
Submissions should address one or more of the following topics:
Clinical diagnosis and rehabilitation strategies for eosinophilic inflammation-driven CLD.
Detailed exploration of the pathophysiology of CLD, with emphasis on eosinophilic inflammation.
Deep dives into the mechanisms underlying eosinophilic inflammation and activation in CLD and their potential clinical applications.
Identifying and analyzing risks associated with eosinophilic inflammation in CLD.